Sun Pharmaceutical Industries Ltd - Sun Pharmaceutical Industries Limited - Press Release
(21 Jul 2025)
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint.